An update on hip fracture risk associated with anticoagulant therapy: warfarin versus direct oral anticoagulants

Figures & data

Table 1. Hip fracture risk associated with use of DOACs/NOACs versus warfarin in three recent cohort studies.

	adjusted hazard ratio	95% confidence interval	p value
Binding C, et al. (2019) [7]	0.91	0.74–1.13	0.39
Lutsey PL, et al. (2020) [8]	0.91	0.78–1.07	0.27
Without osteoporosis	1.06	0.86–1.30
With osteoporosis	0.74	0.58–0.96	0.03*
Huang HK, et al. (2020) [9]	0.85	0.70–1.04	0.12
Overall of the three studies [10]	0.89	0.80–0.99	0.04

*P value for interaction

Binding C, Olesen JB, Abrahamsen B, et al. Osteoporotic fractures in patients with atrial fibrillation treated with conventional versus direct anticoagulants. J Am Coll Cardiol. 2019;74(17):2150–2158.

 PubMed Web of Science ®Google Scholar

Lutsey PL, Norby FL, Ensrud KE, et al. Association of anticoagulant therapy with risk of fracture among patients with atrial fibrillation. JAMA Intern Med. 2020;180(2):245–253.

 PubMed Web of Science ®Google Scholar

Huang HK, Liu PP, Hsu JY, et al. Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study. Eur Heart J. 2020;41(10):1100–1108.

 PubMed Web of Science ®Google Scholar

Huang HK, Yeh JI, Loh CH. Hip fracture risk in patients with atrial fibrillation receiving oral anticoagulants: a meta-analysis based on current observational studies. Eur Heart J. 2020;41(30):2919-2920.

 Web of Science ®Google Scholar